Integrated bioinformatics profiling of the lysine demethylase gene family in breast cancer

Abstract Purpose Lysine demethylases (KDMs) are critical regulators of gene expression and chromatin remodeling, playing key roles in cancer development and progression. Given their involvement in epigenetic modifications, KDM family members have emerged as potential therapeutic targets in various malignancies. This study aimed to investigate the expression profiles, prognostic value, genetic alterations, and drug sensitivity associations of KDM genes across breast cancer (BC) using comprehensive bioinformatics analyses. Methods We utilized multiple online databases, including UALCAN, bc-GenExMiner, Kaplan-Meier Plotter, cBioPortal, STRING, Enrichr, MethSurv, GSCALite, and TIMER, to analyze mRNA expression patterns, clinicopathological correlations, survival outcomes (overall survival [OS] and relapse-free survival [RFS]), genetic alterations, protein-protein interaction (PPI) networks, Gene Ontology (GO) and KEGG pathways, CpG methylation, drug sensitivity, and immune infiltration in BC and pan-cancer contexts. Results KDM genes exhibited distinct expression patterns across BC subtypes, with significant associations with OS (e.g., KDM5B, HR = 1.5, p < 0.05) and RFS. Genetic alterations, primarily amplifications, were frequent, with KDM5B showing the highest rate (18%). PPI analysis identified KDM6A, KDM6B, and KDM1A as key hubs. GO and KEGG analyses linked KDMs to histone demethylation, chromatin remodeling, and metabolic pathways. CpG methylation analysis revealed prognostic relevance, with 35 CpG sites in KDM2B significantly associated with survival ( p < 0.05). Drug sensitivity analysis showed negative correlations between KDM expression (e.g., KDM2B, r =-0.51, FDR = 1.11E-49) and chemotherapy response (e.g., Methotrexate, Doxorubicin). TIMER analysis highlighted KDMs’ immunomodulatory roles, particularly in CD8 + T cells (KDM5A, r = 0.387, p = 3.43e-36), macrophages, and dendritic cells. Conclusions Our findings provide novel insights into the multifaceted roles of KDM genes in BC, emphasizing their potential as prognostic biomarkers and therapeutic targets.

Authors

Institutions

Publication Details

Journal
Discover Biotechnology
Published
2026-03-29
DOI
https://doi.org/10.1007/s44340-026-00055-0
Primary Topic
Epigenetics and DNA Methylation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Integrated bioinformatics profiling of the lysine demethylase gene family in breast cancer

Zohreh Mirzaei, Tahereh Barati, Amir Ebrahimi, Mahmoud Shekari Khaniani
Discover Biotechnology
Epigenetics and DNA Methylation
article

Integrated bioinformatics profiling of the lysine demethylase gene family in breast cancer

Zohreh Mirzaei, Tahereh Barati, Amir Ebrahimi, Mahmoud Shekari Khaniani
article en

Abstract

Abstract Purpose Lysine demethylases (KDMs) are critical regulators of gene expression and chromatin remodeling, playing key roles in cancer development and progression. Given their involvement in epigenetic modifications, KDM family members have emerged as potential therapeutic targets in various malignancies. This study aimed to investigate the expression profiles, prognostic value, genetic alterations, and drug sensitivity associations of KDM genes across breast cancer (BC) using comprehensive bioinformatics analyses. Methods We utilized multiple online databases, including UALCAN, bc-GenExMiner, Kaplan-Meier Plotter, cBioPortal, STRING, Enrichr, MethSurv, GSCALite, and TIMER, to analyze mRNA expression patterns, clinicopathological correlations, survival outcomes (overall survival [OS] and relapse-free survival [RFS]), genetic alterations, protein-protein interaction (PPI) networks, Gene Ontology (GO) and KEGG pathways, CpG methylation, drug sensitivity, and immune infiltration in BC and pan-cancer contexts. Results KDM genes exhibited distinct expression patterns across BC subtypes, with significant associations with OS (e.g., KDM5B, HR = 1.5, p < 0.05) and RFS. Genetic alterations, primarily amplifications, were frequent, with KDM5B showing the highest rate (18%). PPI analysis identified KDM6A, KDM6B, and KDM1A as key hubs. GO and KEGG analyses linked KDMs to histone demethylation, chromatin remodeling, and metabolic pathways. CpG methylation analysis revealed prognostic relevance, with 35 CpG sites in KDM2B significantly associated with survival ( p < 0.05). Drug sensitivity analysis showed negative correlations between KDM expression (e.g., KDM2B, r =-0.51, FDR = 1.11E-49) and chemotherapy response (e.g., Methotrexate, Doxorubicin). TIMER analysis highlighted KDMs’ immunomodulatory roles, particularly in CD8 + T cells (KDM5A, r = 0.387, p = 3.43e-36), macrophages, and dendritic cells. Conclusions Our findings provide novel insights into the multifaceted roles of KDM genes in BC, emphasizing their potential as prognostic biomarkers and therapeutic targets.

Discover BiotechnologyVol. 3(1)
Tabriz University of Medical Sciences (IR)
Good health and well-being
Openalex Percentile: Top 4%
Epigenetics and DNA Methylation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.